Company: PTPI
Filing Date: 2025-03-07
Form Type: PRE 14A
Source: 0001104659-25-021794
Chunk: 25

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-07
Form: PRE 14A
Chunk 25
---
 dilutive issuance or announcement thereof (subject to a floor price of $0.1465 prior to the Stockholder
Approval Date and a floor price of $0.0586 on the Stockholder Approval Date (such floor price then in effect, the “Series A Floor
Price”) and the number of shares issuable upon exercise of the Series A Warrants will be proportionately adjusted such that
the aggregate exercise price will remain unchanged (the “Dilutive Issuance Provision”).

If at any time on or after the date of issuance there occurs any stock
split, stock dividend, stock combination recapitalization, reverse stock split, or other similar transaction involving our Common Stock
and the lowest daily VWAP during the period commencing five consecutive trading days immediately preceding and the five consecutive trading
days commencing on the date of such event is less than the exercise price of the Series A Warrants then in effect, then the exercise
price of the Series A Warrants will be reduced to the lowest VWAP during such period and the number of shares issuable upon exercise
will be proportionately adjusted such that the aggregate price will remain unchanged, subject to the Series A Floor Price then in effect
(the “Share Combination Event Adjustment”).

<div align='center'>16</div>

Cashless Exercise

If, at the time a holder exercises its Series A Warrants, a registration
statement registering the issuance of the shares of Common Stock underlying the Series A Warrants under the Securities Act is
not then effective or the prospectus contained therein is not available for the issuance of such shares, then the Series A Warrant
may be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the holder shall be entitled
to receive a number of shares equal of our Common Stock in accordance with the formula set forth in the Series A Warrant.

Fundamental Transactions

In the event we consummate a merger or consolidation with or into another
person or other reorganization event in which our Common Stock is converted or exchanged for securities, cash or other property, or we
sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of our assets or we or another person
acquire more than 50% of our outstanding shares of our Common Stock, then following such event, the holders of the Series A Warrants
will be entitled to receive upon exercise of the Series A Warrants the same type and amount of securities, cash or